Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1011)	11/7/2005 9:17:04 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3557

OT <<Mol Cell Biol. 2002 Mar;22(6):1704-13. The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis.>> I though that DX-2240 is Tie-1 antagonist, as Angio-2 is to Tie-2. However, Tie-1 ligands' biologic functions appears opposite to function of the Tie-2 ligands. How you see this complexity (cross-talk between Tie-1/Tie-2 and their ligands) to be resolved by Dyax "small" capacity (man power and resource) in cancer biology? DNA has done some work on Tie-2, but no idea what results are. Miljenko PS: VPHM is true homerun this year. Congratulation!